Lennart van Zellem1, Elisabeth M Utens, Saskia N de Wildt, Nienke J Vet, Dick Tibboel, Corinne Buysse. 1. 1Division of Paediatric Intensive Care, Department of Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands. 2Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.
Abstract
OBJECTIVES: To investigate whether analgesic and sedative drug use during PICU treatment is associated with long-term neurodevelopmental outcome in children who survived meningococcal septic shock. DESIGN: This study concerned a secondary analysis of data from medical and psychological follow-up of a cross-sectional cohort of all consecutive surviving patients with septic shock and purpura requiring intensive care treatment between 1988 and 2001 at the Erasmus MC-Sophia Children's Hospital. At least 4 years after PICU admission, these children showed impairments on several domains of neuropsychological functioning. In the present study, type, number, and dose of sedatives and analgesics were retrospectively evaluated. SETTING: Tertiary care university hospital. PATIENTS: Seventy-seven meningococcal septic shock survivors (median age, 2.1 yr). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Forty-five patients (58%) received one or more analgesic and/or sedative drugs during PICU admission, most commonly benzodiazepines (n = 39; 51%), followed by opioids (n = 23; 30%). In total, 12 different kinds of analgesic or sedative drugs were given. The use and dose of opioids were significantly associated with poor test outcome on full-scale intelligence quotient (p = 0.02; Z = -2.28), verbal intelligence quotient (p = 0.02; Z = -2.32), verbal intelligence quotient subtests (verbal comprehension [p = 0.01; Z = -2.56] and vocabulary [p = 0.01; Z = -2.45]), and visual attention/executive functioning (Trial Making Test part B) (p = 0.03; Z = -2.17). In multivariate analysis adjusting for patient and disease characteristics, the use of opioids remained significant on most neuropsychological tests. CONCLUSIONS: The use of opioids during PICU admission was significantly associated with long-term adverse neuropsychological outcome independent of severity of illness scores in meningococcal septic shock survivors.
OBJECTIVES: To investigate whether analgesic and sedative drug use during PICU treatment is associated with long-term neurodevelopmental outcome in children who survived meningococcal septic shock. DESIGN: This study concerned a secondary analysis of data from medical and psychological follow-up of a cross-sectional cohort of all consecutive surviving patients with septic shock and purpura requiring intensive care treatment between 1988 and 2001 at the Erasmus MC-Sophia Children's Hospital. At least 4 years after PICU admission, these children showed impairments on several domains of neuropsychological functioning. In the present study, type, number, and dose of sedatives and analgesics were retrospectively evaluated. SETTING: Tertiary care university hospital. PATIENTS: Seventy-seven meningococcal septic shock survivors (median age, 2.1 yr). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Forty-five patients (58%) received one or more analgesic and/or sedative drugs during PICU admission, most commonly benzodiazepines (n = 39; 51%), followed by opioids (n = 23; 30%). In total, 12 different kinds of analgesic or sedative drugs were given. The use and dose of opioids were significantly associated with poor test outcome on full-scale intelligence quotient (p = 0.02; Z = -2.28), verbal intelligence quotient (p = 0.02; Z = -2.32), verbal intelligence quotient subtests (verbal comprehension [p = 0.01; Z = -2.56] and vocabulary [p = 0.01; Z = -2.45]), and visual attention/executive functioning (Trial Making Test part B) (p = 0.03; Z = -2.17). In multivariate analysis adjusting for patient and disease characteristics, the use of opioids remained significant on most neuropsychological tests. CONCLUSIONS: The use of opioids during PICU admission was significantly associated with long-term adverse neuropsychological outcome independent of severity of illness scores in meningococcal septic shock survivors.
Authors: Mark J Peters; Andrew Argent; Marino Festa; Stéphane Leteurtre; Jefferson Piva; Ann Thompson; Douglas Willson; Pierre Tissières; Marisa Tucci; Jacques Lacroix Journal: Intensive Care Med Date: 2017-03-17 Impact factor: 17.440
Authors: Liang R Cui; Megan LaPorte; Matthew Civitello; Meg Stanger; Maxine Orringer; Frank Casey; Bradley A Kuch; Sue R Beers; Cynthia A Valenta; Patrick M Kochanek; Amy J Houtrow; Ericka L Fink Journal: J Crit Care Date: 2017-03-07 Impact factor: 3.425
Authors: Martha A Q Curley; David Wypij; R Scott Watson; Mary Jo C Grant; Lisa A Asaro; Ira M Cheifetz; Brenda L Dodson; Linda S Franck; Rainer G Gedeit; Derek C Angus; Michael A Matthay Journal: JAMA Date: 2015-01-27 Impact factor: 56.272
Authors: Alicia G Kachmar; R Scott Watson; David Wypij; Mallory A Perry; Martha A Q Curley Journal: Crit Care Med Date: 2022-02-01 Impact factor: 9.296
Authors: Alia Marie Iqbal O'Meara; Nikki Miller Ferguson; Sidney E Zven; Oliver L Karam; Logan C Meyer; John W Bigbee; Carmen Sato-Bigbee Journal: Crit Care Explor Date: 2020-04-29